1. ALLA AKTIER
  2. NYHETER
  3. XVIVO PERFUSION

Xvivo Perfusion

Nyheter Xvivo Perfusion Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Conference call on Interim Report July-September 2025

Invitation to attend XVIVO’s conference call regarding the interim report July-September 2025. The presentation will be held in English.

Time: Thursday October 23, at 2.00 pm CET / 8.00 am EST

If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. https://events.inderes.com/xvivo/q3-report-2025

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally. https://events.inderes.com/xvivo/q3-report-2025/dial-in

Participants from XVIVO:
Christoffer Rosenblad, CEO
Kristoffer Nordström, CFO
 
A press release containing XVIVO’s interim report July-September 2025 will be released on October 23, 2025 at 7.30 am CET / 1.30 am EST.
 
Before the conference call, slides will be available at the company web page, https://www.xvivogroup.com/investors/reports-and-presentations/

October 13, 2025
Mölndal
XVIVO Perfusion AB (publ)

For further information, please contact:

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Conference call on Interim Report July-September 2025

Datum 2025-10-13, kl 19:00
Källa MFN
Bifogade filer
Conference call on Interim Report July-September 2025